skip to content

eLesor Investments version="1.1" id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 697.5 99.8" style="enable-background:new 0 0 697.5 99.8;" xml:space="preserve" aria-labelledby="title--mwlogoHeader desc--mwlogoHeader" role="img"> eLesor Site Logo A link that brings you back to the homepage.

Sera Prognostics Files for IPO

By Stephen Nakrosis

Women's health diagnostic company Sera Prognostics, Inc. filed for an initial public offering with the Securities and Exchange Commission on Friday.

The company said it is "developing a robust pipeline of novel blood-based biomarker tests for a number of major pregnancy related conditions beyond preterm birth by leveraging the biological insights provided by our proprietary technology platform."

The company also said, "We also believe that the work we perform in pregnancy can ultimately be leveraged more broadly to address other areas in medicine and healthcare."

Entities affiliated with Blue Ox Healthcare Partners, LLC, ATH Holding Company, LLC, Domain Associates, LLC and InterWest Partners X, LP are listed among the company's principal stockholders.

Sera Prognostics didn't give an expected size for its IPO, nor did it provide an anticipated price range.

​Citigroup, Cowen and William Blair are listed as the offering's underwriters.

Write to Stephen Nakrosis at [email protected]




      

Partner Center